Cariprazine Capsules Suppliers & Bulk Manufacturers
Available Forms: Oral Capsules
Available Strengths: 1.5 mg, 3 mg, 4.5 mg, 6 mg
Reference Brands: Vraylar®(US); Reagila®(EU)
Category:
Antipsychotropic Drugs
Cariprazine is an atypical antipsychotic that works as a partial agonist at dopamine D2 and D3 receptors, with a higher affinity for D3, and serotonin 5-HT1A receptor partial agonism, along with 5-HT2A receptor antagonism. This receptor activity helps balance dopamine and serotonin levels in the brain. Cariprazine capsules are used to treat schizophrenia, bipolar I disorder (manic or mixed episodes), and as an adjunctive treatment for major depressive disorder (MDD). Its unique D3 activity may offer cognitive and mood-related benefits with a favorable side effect profile.
Cariprazine Capsules is available in Oral Capsules
and strengths such as 1.5 mg, 3 mg, 4.5 mg, 6 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cariprazine Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cariprazine Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cariprazine capsules are FDA-approved in the U.S. for schizophrenia, bipolar I disorder (manic/mixed episodes), and as adjunctive therapy for major depressive disorder (MDD). In the EU, they are approved under the brand name Reagila for schizophrenia via centralized EMA procedures. Regulatory requirements include GMP-compliant manufacturing, robust clinical data, and safety documentation addressing extrapyramidal symptoms (EPS), akathisia, and metabolic effects. U.S. labeling must follow FDA guidance with boxed warnings for elderly dementia-related psychosis. EMA approval mandates detailed pharmacovigilance systems and Risk Management Plans (RMPs). To explore dossier-ready Cariprazine capsules, visit Pharmatradz.com — your global B2B pharma sourcing partner.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing